Order Article Reprints

Bohr A, Nascimento TL, Harmankaya N, Weisser JJ, Wang Y, Grohganz H, Rades T, Löbmann K. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules. 2019; 24(2):266. https://doi.org/10.3390/molecules24020266

Bohr, Adam, Thais Leite Nascimento, Necati Harmankaya, Johan Juhl Weisser, Yingya Wang, Holger Grohganz, Thomas Rades, and Korbinian Löbmann. 2019. "Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy" Molecules 24, no. 2: 266. https://doi.org/10.3390/molecules24020266

Bohr, A., Nascimento, T. L., Harmankaya, N., Weisser, J. J., Wang, Y., Grohganz, H., Rades, T., & Löbmann, K. (2019). Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules, 24(2), 266. https://doi.org/10.3390/molecules24020266